Healthtech Investors: JSL Health Capital Fund II Reports $93.1 Million for AI and Healthcare Companies

JSL Health Capital Fund II, L.P. filed with the US Securities and Exchange Commission on November 6, 2026, reporting $93.1 million sold. Alexander Turkeltaub is named as key person, and the filing carries a biotech and life sciences sector tag. It was the second largest venture-tagged filing of the day and the largest with a healthcare tag. This article sets out what the filing shows, what public sources say about JSL Health Capital, and how healthtech founders can use the information. Public information on this firm is thin and sources disagree on basic facts, so we say plainly what we could and could not confirm.

What the Filing Shows

The fund reports $93.1 million sold, filed November 6, 2026. On that day 45 vehicles carried the venture capital tag and reported $490.8 million combined, so this fund is about 19 percent of the total. Six vehicles reported $0, which usually means a new vehicle with no amount yet. The filing does not say how much of the $93.1 million is committed versus called, or how large the final fund will be. We found no press release or announcement for a Fund II, and we found no earlier fund names or sizes in public listings, so we cannot say how Fund II compares with a first fund.

About JSL Health Capital

Several profiles name Alex Turkeltaub as founder and managing partner of JSL Health Capital, which describes itself as an investor at the intersection of healthcare, artificial intelligence and data. Descriptions vary between a growth equity firm and an investment firm with a venture studio that backs late seed and growth stage healthcare companies using AI, data and software. Third-party profiles also disagree on when and where the firm was founded: dates range from 2018 to 2022, with 2020 the most common, and locations include Washington, DC and Delaware. One listing shows an SEC-registered investment adviser. PitchBook lists around 30 investments, with the most recent on July 20, 2026 in Radial Health. We could not verify these details from the firm's own documents.

Why Healthcare AI Capital Matters

Healthcare AI companies face a longer path to revenue than most software businesses. Selling into hospitals, payers or life sciences firms means long contracts, compliance reviews, and in some cases regulatory clearance. That is why funds that focus on the sector, with partners who know buyers and regulators, can be more useful than a generalist at the same cheque size. A fund targeting late seed through growth rounds usually writes larger cheques than a pre-seed fund and expects revenue or pilot contracts.

How Healthtech Founders Should Approach It

Founders raising a late seed or Series A round in healthcare AI should prepare evidence of deployment and not just a model. Investors in this category typically want to see signed pilots or paying customers, clear data rights, a plan for compliance, and the time it takes from first contact to contract. Bring your sales cycle length and your gross margin, since AI compute and clinical support can compress margins.

Know your instrument and terms before the first call. At late seed, a SAFE or a priced round are both common, so decide how much dilution you will accept and model the effect on later rounds. Ask whether the fund will act as lead investorand whether it reserves capital for follow-ons, which matters for a company that may need several rounds before revenue scales. Treat the process as two-way due diligence: ask for founder references from portfolio companies, and ask what help the firm gives on hospital and payer introductions.

What Fund Managers Can Learn

JSL's public footprint is small, yet it reports a fund of nearly $100 million. That shows a manager can raise institutional-size capital with limited press coverage, but it also means limited partners and founders must rely on documents, not reputation. Emerging managers who want to be easier to evaluate should publish a clear thesis, a portfolio list, and fund history, because the gap between a $93.1 million filing and a missing public profile creates questions that a website can answer.

Today's Venture Filing Picture

The largest venture-tagged filings on November 6 were:

• Fund V, a series of Browder Capital Early Stage Ventures, LP: $100.0 million (Joshua Browder), tagged as a single-deal vehicle
• JSL Health Capital Fund II, L.P.: $93.1 million (Alexander Turkeltaub)
• 01A Bald Eagle 02, L.P.: $72.6 million (Richard Costolo)
• K5 Tech Fund II, LP, Series 212: $55.4 million (Bryan J. Baum), tagged as a single-deal vehicle
• Encouraging Mountain, L.P.: $40.0 million (Mission Opportunity GP, LLC)

What We Could Not Confirm

We could not confirm that a Fund II was announced, its target size, its limited partners, or its portfolio. Founding date, location and strategy descriptions differ across third-party profiles. We found no filing explanation of how much of the amount has been called.

Key Takeaways

JSL Health Capital Fund II reported $93.1 million on November 6, the largest healthcare-tagged venture filing of the day. The firm focuses on AI and healthcare but has a small public record, so founders should request portfolio references and fund details before pitching. Prepare deployment evidence, margin data and clear terms.

Browse the investor directory to compare healthcare investors by stage, and explore active capital on AngelLinx @ angellinx.ai/register.

AngelLinx Intelligence | angellinx.ai